Quick Win By The Algorithm: CLSN Vaults Skyward On Promising Clinical Trial Data

Quick Win By The Algorithm

On September 26th, 2017, I Know First issued a bullish 7 day forecast for Celsion Corporation (NASDAQ: CLSN). The forecast showed a signal of 3.30 and a predictability of 0.19. In accordance with the forecast, CLSN’s stock returned 274.07% over this period, solidifying another quick win by the I Know First algorithm.

Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer.  ThermoDox is also under Phase II clinical trials for recurrent chest wall breast cancer. Celsion is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Encouraging Results

Celsion Corporation vaulted skyward on October 3rd due to the release of extremely promising clinical data from its OVATION program.  The stock price had gains of over 300% for the day.  This program uses Celsion’s developmental asset, GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers.  The OVATION program assessed how GEN-1 affected ovarian cancer cells in newly diagnosed patients with stage III and IV ovarian cancer when used in combination with standard care.

The results to date have been very encouraging.  All fourteen patients reflected a 100% disease control rate (DCR) which means all of the patients had a response to the treatment.  This also means that the treatment options for late stage patients could get expanded.  This would be a game changer for many patients.  Celsion is planning on filing the Phase II design with the FDA by the end of the year.

Current I Know First subscribers received this bullish CLSN forecast on September 26th, 2017


Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.